{"id":242070,"date":"2026-08-02T09:48:42","date_gmt":"2026-08-02T14:48:42","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2026\/08\/hypereosinophilia-with-pseudomonas-aeruginosa-infection-in-patients-with-asthma-on-antiinterleukin5-biologics"},"modified":"2026-08-02T09:48:42","modified_gmt":"2026-08-02T14:48:42","slug":"hypereosinophilia-with-pseudomonas-aeruginosa-infection-in-patients-with-asthma-on-antiinterleukin5-biologics","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2026\/08\/hypereosinophilia-with-pseudomonas-aeruginosa-infection-in-patients-with-asthma-on-antiinterleukin5-biologics","title":{"rendered":"Hypereosinophilia With Pseudomonas aeruginosa Infection in Patients With Asthma on AntiInterleukin5 Biologics"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/hypereosinophilia-with-pseudomonas-aeruginosa-infection-in-patients-with-asthma-on-antiinterleukin5-biologics.jpg\"><\/a><\/p>\n<p>Biologic therapies targeting IL-5 or its receptor reduce eosinophilia and exacerbations in asthma. Breakthrough eosinophilic attacks are usually considered biologic failure. We report 2 patients with severe asthma receiving mepolizumab or benralizumab who developed relapsing hypereosinophilia associated with <i>Pseudomonas <i>aeruginosa<\/i><\/i> airway infection. Case 1 was a 71-year-old woman in Canada with severe eosinophilic asthma and COPD overlap whose eosinophils suddenly rebounded to 1,400 cells\/\u03bcL during an acute exacerbation while on mepolizumab, coinciding with <i>P <i>aeruginosa<\/i><\/i> infection and resolving after antibiotic treatment.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biologic therapies targeting IL-5 or its receptor reduce eosinophilia and exacerbations in asthma. Breakthrough eosinophilic attacks are usually considered biologic failure. We report 2 patients with severe asthma receiving mepolizumab or benralizumab who developed relapsing hypereosinophilia associated with Pseudomonas aeruginosa airway infection. Case 1 was a 71-year-old woman in Canada with severe eosinophilic asthma and [\u2026]<\/p>\n","protected":false},"author":662,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,1522],"tags":[],"class_list":["post-242070","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-innovation"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/242070","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/662"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=242070"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/242070\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=242070"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=242070"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=242070"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}